Sapanisertib Fast Track for NRF2-Mutated Squamous NSCLC
The Food and Drug Administration (FDA) has granted Fast Track designation to sapanisertib for the treatment of adults and unresectable...
NRF2Mutated
The Food and Drug Administration (FDA) has granted Fast Track designation to sapanisertib for the treatment of adults and unresectable...
